Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
September 19, 2015 16:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 19, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition
September 19, 2015 08:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 19, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
September 14, 2015 08:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference
September 01, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics,...
Arno Therapeutics Receives Authorization to Proceed With Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
August 18, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other...
Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update
August 14, 2015 17:03 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other...
Arno Therapeutics Announces Issuance of First Onapristone Patent
June 04, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., June 4, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and...
Arno Therapeutics Announces Cooperative Research and Development Agreement With US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12
June 03, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., June 3, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the...
Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
May 28, 2015 11:15 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on developing therapeutics in cancer and other life...
Arno Therapeutics Reports First Quarter 2015 Financial and Business Update
May 15, 2015 16:35 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life...